Arovella Therapeutics Ltd
ALA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
stocks
Here’s how to value a share
Our best resources to help investors determine the value of a share.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
GyG punished by market after solid earnings
Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,245.00 | 66.30 | -0.71% |
CAC 40 | 7,843.04 | 126.65 | -1.59% |
DAX 40 | 24,273.12 | 89.97 | -0.37% |
Dow JONES (US) | 45,388.41 | 243.33 | -0.53% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,829.91 | 490.77 | 1.94% |
NASDAQ | 21,537.16 | 40.63 | 0.19% |
Nikkei 225 | 42,807.82 | 174.53 | 0.41% |
NZX 50 Index | 13,079.50 | 36.74 | 0.28% |
S&P 500 | 6,460.26 | 6.65 | -0.10% |
S&P/ASX 200 | 8,972.40 | 71.70 | -0.79% |
SSE Composite Index | 3,883.56 | 57.80 | 1.51% |